Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2

Status

Completed 4Withdrawn 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Tumor-Agnostic 2Gynecologic 2Thoracic 1Plasma cell 1Gastrointestinal 1Breast 1

Conditions

Neoplasms 4Breast Neoplasms 4Pancreatic Neoplasms 3Ovarian Neoplasms 3Stomach Neoplasms 2Prostatic Neoplasms 2Tongue Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumor 1Small Cell Lung Carcinoma 1Sarcoma, Endometrial Stromal 1Sarcoma 1Rhabdomyosarcoma 1Pleural Effusion, Malignant 1Neoplasms, Plasma Cell 1Melanoma 1Lymphangioleiomyomatosis 1Lung Neoplasms 1Liver Neoplasms 1Liposarcoma 1Leiomyosarcoma 1Histiocytoma, Malignant Fibrous 1Fibrosarcoma 1Fallopian Tube Neoplasms 1Esophageal Neoplasms 1Dermatofibrosarcoma 1Colonic Neoplasms 1Choriocarcinoma 1Cholangiocarcinoma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Gemcitabine 109Paclitaxel 92Carboplatin 79pembrolizumab 75Bevacizumab 75Surveys and Questionnaires 70Docetaxel 69Cisplatin 67Nivolumab 48Exercise 48Capecitabine 48Cyclophosphamide 47Sorafenib 43Fluorouracil 43Irinotecan 42Pemetrexed 37Albumin-Bound Paclitaxel 35Radiotherapy 34Dexamethasone 34Blood Specimen Collection 34Oxaliplatin 31Leucovorin 31Erlotinib Hydrochloride 31trametinib 30130-nm albumin-bound paclitaxel 29Cetuximab 28Therapeutics 26Ipilimumab 26Standard of Care 25Methods 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Completed × Neoplasms × saracatinib × Clear all
NCT02085603 2018-04-13

SarCaBon

Sheffield Teaching Hospitals NHS Foundation Trust

Phase 2 Completed
12 enrolled
Tumor-Agnostic

Neoplasms

NCT00610714 2012-12-18

OVERT-1

AstraZeneca

Phase 2 Completed
211 enrolled 12 charts
Gynecologic

Neoplasms, Ovarian Neoplasms

NCT00496028 2010-09-22

Phase I Study in Patients With Solid Tumours

AstraZeneca

Phase 1 Completed
148 enrolled
Tumor-Agnostic

Neoplasms

NCT00475956 2010-04-15

Safety and Tolerability Study of AZD2171 in Combination With AZD0530 in Patients With Advanced Solid Tumours

AstraZeneca

Phase 1 Completed
40 enrolled
BreastGastrointestinalGynecologicPlasma cellThoracic

Breast Neoplasms, Choriocarcinoma, Colonic Neoplasms, Liver Neoplasms, Lung Neoplasms, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Cholangiocarcinoma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡